Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells

[1] Van Acker HH(2015)Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy Oncoimmunology 4 e1021538-609

[2] Anguille S(2001)Regulation of cutaneous malignancy by gammadelta T cells Science 294 605-133

[3] Van Tendeloo VF(2010)Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin J Immunol 185 126-390

[4] Lion E(2006)Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom 70 379-323

[5] Girardi M(2008)Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients J Immunother 31 313-945

[6] Oppenheim DE(2015)The prognostic landscape of genes and infiltrating immune cells across human cancers Nat Med 21 938-668

[7] Steele CR(2014)Clinical applications of gamma delta T cells with multivalent immunity Front Immunol 5 636-145

[8] He W(2015)The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy Cell Mol Immunol 12 656-775

[9] Hao J(2016)Acute myeloid leukemia—major progress over four decades and glimpses into the future Am J Hematol 91 131-2704

[10] Dong S(2015)Management of older or unfit patients with acute myeloid leukemia Leukemia 29 770-468

[1] Van Acker HH(2015)Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy Oncoimmunology 4 e1021538-609

[2] Anguille S(2001)Regulation of cutaneous malignancy by gammadelta T cells Science 294 605-133

[3] Van Tendeloo VF(2010)Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of eomesodermin J Immunol 185 126-390

[4] Lion E(2006)Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom 70 379-323

[5] Girardi M(2008)Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients J Immunother 31 313-945

[6] Oppenheim DE(2015)The prognostic landscape of genes and infiltrating immune cells across human cancers Nat Med 21 938-668

[7] Steele CR(2014)Clinical applications of gamma delta T cells with multivalent immunity Front Immunol 5 636-145

[8] He W(2015)The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy Cell Mol Immunol 12 656-775

[9] Hao J(2016)Acute myeloid leukemia—major progress over four decades and glimpses into the future Am J Hematol 91 131-2704

[10] Dong S(2015)Management of older or unfit patients with acute myeloid leukemia Leukemia 29 770-468